Saturday 17 October 2026
Export CHRS’s income statement to Excel — free account
Coherus Oncology, Inc.
CHRS Healthcare Biotechnology
In the quarter to June 2026, revenue grew 39.5%, EPS fell 105.1%, free cash flow fell 33.2% and total debt rose 1.03%, each against the same quarter a year earlier.
1.00
0.07
−6.54%
Follow CHRS
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
6 | 4 | 3 | 1 | 2 | — | — | — | 2 | 3 |
P/E ratio |
0.97 | 5.11 | 0.00 | 0.00 | 0.00 | 9.39 | 14.07 | — | 0.00 | 0.00 |
Altman Z-Score |
(8.83) | (5.93) | (3.67) | (4.03) | (0.95) | 2.12 | 1.82 | — | (8.39) | (0.14) |
P/S ratio |
3.94 | 5.99 | 1.15 | 3.13 | 3.69 | 2.61 | 3.52 | — | 211.43 | 6.17 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.45 | 47.30 | — | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(20.15) | (13.65) | (9.10) | (9.61) | (3.25) | 3.67 | (1.34) | — | (20.17) | (10.19) |
P/Operating CF |
(8.44) | 5.53 | (22.85) | (6.61) | (23.01) | 37.47 | 70.86 | — | (16.96) | (13.51) |
Beneish M-Score |
(3.44) | (3.21) | (1.39) | (2.77) | (4.41) | (2.50) | — | — | — | 4.91 |
P/B ratio |
2.73 | 0.00 | 0.00 | 0.00 | 12.32 | 4.42 | 11.93 | — | 16.62 | 60.64 |
Price to Tangible BV |
11.26 | 0.00 | 0.00 | 0.00 | 12.79 | 4.47 | 12.35 | — | 18.81 | 74.32 |
EV/Sales |
4.89 | 17.89 | 2.55 | 4.47 | 4.04 | 2.33 | 3.53 | — | 200.86 | 6.04 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.95 | 11.33 | — | 0.00 | 0.00 |
EV/Operating CF |
(1.49) | (23.09) | (3.75) | (3.92) | (35.28) | 7.18 | 44.36 | — | (2.41) | (4.55) |
EV/FCF |
(1.48) | (22.08) | (3.73) | (3.88) | (34.10) | 7.54 | 47.41 | — | (2.35) | (4.43) |
Quick Ratio |
1.36 | 0.88 | 1.14 | 2.17 | 3.27 | 4.79 | 2.78 | 2.18 | 4.47 | 2.25 |
Current Ratio |
1.47 | 1.21 | 1.43 | 2.75 | 3.64 | 5.27 | 2.98 | 2.54 | 5.12 | 2.86 |
Net Debt/EBITDA |
0.76 | (0.71) | (1.78) | (1.10) | 0.03 | (0.86) | 0.01 | (0.15) | 0.11 | 0.22 |
Debt/Assets |
14.34% | 59.07% | 75.19% | 97.96% | 60.10% | 48.00% | 43.62% | 103.64% | 62.49% | 56.17% |
Debt/Equity |
0.61 | (2.01) | (2.45) | (3.43) | 4.18 | 1.44 | 1.70 | (2.67) | 3.33 | 5.18 |
Asset Turnover |
0.12 | 0.05 | 0.46 | 0.36 | 0.43 | 0.76 | 1.40 | 0.00 | 0.01 | 0.97 |
Operating CF/Net income |
(0.82) | (0.72) | 0.74 | 0.83 | 0.13 | 1.17 | 0.32 | 0.76 | 0.84 | 1.98 |
Capex/Depreciation |
0.00 | 0.00 | (0.08) | (0.55) | (0.37) | (2.50) | (0.56) | (0.24) | (1.35) | (2.17) |
Interest Coverage |
(20.12) | (18.60) | (5.01) | (7.91) | (11.49) | 7.39 | 6.12 | (21.11) | (24.30) | (14.53) |
| (473.47%) | (17.52%) | 143.81% | 1,470.09% | (151.62%) | 68.49% | 269.68% | 5,197.10% | (954.80%) | (2,049.69%) | |
| 47.54% | 5.29% | (42.85%) | (50.29%) | (37.75%) | 21.15% | 35.34% | (159.75%) | (139.65%) | (65.16%) | |
ROIC |
0.00% | (1,795.44%) | (78.30%) | (113.10%) | (185.69%) | 67.92% | 63.58% | 0.00% | (2,805.20%) | 0.00% |
Return on Tangible Assets |
248.32% | 46.60% | (159.68%) | (116.10%) | (64.54%) | 20.93% | 38.41% | (361.98%) | (183.41%) | (109.89%) |
Average Days of Receivables |
159.41 | 1,692.07 | 369.65 | 190.18 | 137.51 | 120.47 | 145.55 | — | 0.00 | 3.57 |
Research and Development Expense of Revenue |
258.20% | 348.00% | 42.54% | 94.46% | 111.19% | 30.00% | 26.45% | 0.00% | 10,436.31% | 133.84% |
Selling, General and Administrative Expense of Revenue |
238.56% | 475.51% | 74.64% | 94.05% | 51.97% | 29.23% | 38.49% | 0.00% | 4,582.46% | 27.14% |
Intangible Assets out of Total Assets |
0.18 | 0.12 | 0.11 | 0.01 | 0.01 | 0.00 | 0.01 | 0.04 | 0.02 | 0.02 |
Share Based Compensation of Revenue |
40.23% | 105.35% | 16.76% | 24.04% | 15.73% | 8.02% | 9.43% | 0.00% | 2,146.34% | 14.42% |
Graham Net Nets |
0.06 | (1.51) | (1.17) | (0.36) | 0.02 | 0.17 | 0.03 | — | 0.03 | 0.00 |
Graham Number |
4.14 | 0.00 | 10.90 | 12.24 | 0.00 | 12.80 | 6.59 | — | 0.00 | 0.00 |
Earnings Yield |
102.82% | 19.57% | (81.85%) | (44.18%) | (24.19%) | 10.64% | 7.11% | — | (47.64%) | (11.32%) |
Free Cash Flow Yield |
(83.84%) | (13.53%) | (59.47%) | (36.81%) | (3.22%) | 11.84% | 2.11% | — | (40.37%) | (22.08%) |
Revenue per Share |
0.36 | 0.23 | 2.73 | 2.72 | 4.33 | 6.66 | 5.11 | 0.00 | 0.03 | 4.54 |
Operating CF per Share |
(1.18) | (0.18) | (1.86) | (3.11) | (0.50) | 2.16 | 0.41 | (2.45) | (3.77) | (6.03) |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.03) | (0.02) | (0.10) | (0.03) | (0.01) | (0.09) | (0.16) |
Free Cash Flow per Share |
(1.18) | (0.18) | (1.86) | (3.13) | (0.51) | 2.06 | 0.38 | (2.46) | (3.86) | (6.18) |
Cash per Share |
1.47 | 1.10 | 1.25 | 2.47 | 5.53 | 7.58 | 2.55 | 1.11 | 2.39 | 2.98 |
Shareholders Equity per Share |
0.52 | (1.15) | (2.05) | (1.77) | 1.30 | 3.93 | 1.51 | (0.59) | 0.57 | 0.46 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.52 | (1.15) | (2.05) | (1.77) | 1.30 | 3.93 | 1.51 | (0.59) | 0.57 | 0.46 |
Free Cash Flow |
(138.51) | (20.44) | (175.17) | (243.16) | (38.72) | 146.91 | 26.53 | (160.05) | (204.86) | (259.06) |
Working Capital |
66.32 | 58.60 | 143.86 | 242.54 | 437.00 | 621.83 | 228.04 | 51.17 | 117.08 | 105.11 |
Capital Expenditures |
— | — | (0.29) | (2.04) | (1.29) | (7.23) | (1.82) | (0.79) | (4.57) | (6.51) |
Net Current Asset Value |
9.38 | (238.94) | (347.40) | (237.03) | 20.72 | 206.80 | 39.30 | (53.62) | 13.40 | 2.36 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.08 | 11.67 | — | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.02 | 0.01 | 0.00 | 2.94 | 0.03 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.94 | 11.64 | — | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
2.92 | 2.05 | 0.74 | 0.42 | 0.44 | 0.29 | 0.56 | 0.49 | 0.27 | 0.28 |
Cash ROIC |
(51.27%) | (7.89%) | (44.05%) | (46.29%) | (4.19%) | 11.98% | 5.75% | (116.91%) | (79.06%) | (105.90%) |
Accounts Receivable Turnover |
0.60 | 0.14 | 1.39 | 1.81 | 2.33 | 3.18 | 4.95 | — | 0.00 | 111.21 |
Accounts Payable Turnover |
0.72 | 0.27 | 6.80 | 5.06 | 3.67 | 1.83 | 0.83 | 0.21 | 0.00 | 0.00 |
Inventory Turnover |
3.74 | 0.26 | 3.14 | 1.83 | 1.41 | 1.39 | 2.98 | 0.03 | — | — |
Average Days of Payables |
261.98 | 1,190.15 | 80.85 | 60.03 | 102.41 | 147.30 | 555.37 | 1,725.60 | 0.00 | 0.00 |
Days of Inventory on Hand |
83.81 | 175.95 | 143.72 | 202.03 | 238.57 | 428.63 | 209.60 | 187.18 | — | — |
Average Receivables |
70.38 | 191.43 | 185.24 | 116.49 | 140.03 | 149.52 | 71.93 | — | — | 1.71 |
Average Payables |
19.19 | 31.84 | 23.37 | 13.84 | 15.68 | 20.59 | 20.64 | 15.50 | 18.15 | 25.04 |
Average Inventory |
3.69 | 33.41 | 50.70 | 38.22 | 40.94 | 27.02 | 5.73 | 129.33 | — | — |
Average Assets |
353.44 | 539.07 | 555.23 | 580.09 | 760.49 | 625.29 | 254.20 | 131.04 | 170.55 | 195.43 |
Average Common Equity |
(35.49) | (162.71) | (165.42) | (19.85) | 189.35 | 193.09 | 33.31 | (4.03) | 24.94 | 6.21 |
Columns are period end dates